http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28224852

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Journal Article
endingPage 1643
issn 0007-0920
1532-1827
issueIdentifier 11
pageRange 1637-1643
publicationName British Journal of Cancer
startingPage 1637
bibliographicCitation Desar IME, Timmer-Bonte JNH, Burger DM, van der Graaf WTA, van Herpen CML. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. British Journal of Cancer. 2010 Nov 02;103(11):1637–43. doi: 10.1038/sj.bjc.6605777.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a7e40c751b325b227f65295c00124e2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_763f7ac1eb18844a7ea84a939516a148
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_481b4083ee5acb74e2f15166df578f22
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_01310fa4626021d186b6fcc1d5fd20f6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_444197d895e5887b35be91dbe46d8437
date 2010-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1038/sj.bjc.6605777
https://pubmed.ncbi.nlm.nih.gov/PMC2994217
https://pubmed.ncbi.nlm.nih.gov/21045832
isPartOf https://portal.issn.org/resource/ISSN/0007-0920
https://portal.issn.org/resource/ISSN/1532-1827
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1765
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/
title A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
discusses http://id.nlm.nih.gov/mesh/M0029863
http://id.nlm.nih.gov/mesh/M0018233
http://id.nlm.nih.gov/mesh/M0014833
http://id.nlm.nih.gov/mesh/M0185196
http://id.nlm.nih.gov/mesh/M0002336
http://id.nlm.nih.gov/mesh/M0446095
http://id.nlm.nih.gov/mesh/M0016578
http://id.nlm.nih.gov/mesh/M0543256
hasSubjectTerm http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103
http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10064
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216239
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7507
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d0bb789479d34dbc0811f92fc2bc5049
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cb58e6788fc9a69c674bb00f98bffc14
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11386
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284616
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6910
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127476202
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127638306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248184126
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129683629
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129046631
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128132375
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128611606
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247499656
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248766214
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID242749350
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID244328266

Total number of triples: 62.